| rivaroxaban / Generic mfg. |
NCT01344954 / 2010-023383-40: Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery |
|
|
| Completed | 2b | 632 | Europe, RoW | TB-402, Rivaroxaban, Xarelto | ThromboGenics, BioInvent International AB | Prophylaxis of Venous Thromboembolic Events | 12/11 | 05/12 | | |
| Recruiting | 2 | 600 | | | South East Sydney and Illawarra Area Health Service , Thrombosis and Haemostasis Society of Australia and New Zealand | Cancer-associated thrombosis, Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism | | | | |
ODIXa-HIP2, NCT00398905: Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement |
|
|
| Completed | 2 | 726 | Europe, RoW | Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin | Bayer | Venous Thromboembolism | | 09/04 | | |
NCT00402467: An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study |
|
|
| Completed | 2 | 613 | US, Canada | Rivaroxaban (BAY59-7939), Rivaroxaban, (BAY59-7939), Enoxaparine | Bayer | Venous Thromboembolism | 11/04 | 11/04 | | |
ACTRN12605000601639: Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis. A phase II dose finding and proof of principle trial.
ODIXa-DVT |
|
|
| Completed | 2 | 600 | | | Bayer Australia Ltd, Bayer Australia Ltd | Deep vein thrombosis | | | | |
| Completed | 2 | 877 | Europe, RoW | Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin | Bayer | Venous Thromboembolism | 07/05 | 07/05 | | |
ACTRN12605000597695: Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The Einstein-DVT dose-finding study. |
|
|
| Completed | 2 | 520 | | | Bayer Australia Ltd, Bayer Australia Ltd | Acute symptomatic deep-vein thrombosis | | | | |
NCT00839163 / 2004-001083-43: Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT) |
|
|
| Completed | 2 | 613 | Europe, Canada, RoW | Xarelto (Rivaroxaban, BAY59-7939), Enoxaparin/Vitamin K-Antagonist | Bayer | Venous Thrombosis, Deep Vein Thrombosis | 10/05 | 10/05 | | |
| Completed | 2 | 543 | US, Canada, Europe, RoW | Xarelto (Rivaroxaban, BAY59-7939), (LMW) Heparin + Vitamin K Antagonist | Bayer, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Venous Thromboembolism | | 12/05 | | |
NCT00786422 / 2008-003303-31: Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer |
|
|
| Completed | 2 | 25 | Europe, RoW | Rivaroxaban (Xarelto, BAY59-7939) | Bayer, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Venous Thrombosis, Deep Vein Thrombosis | 05/11 | 06/11 | | |
ERIKA, NCT01629381: Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy |
|
|
| Completed | 2 | 500 | Europe | Rivaroxaban, Xarelto, placebo | University of Padova | Venous Thromboembolism, Haemorrhage | 03/14 | 03/14 | | |
NCT02271399: Comparative Study of Prophylactic Agent for Venous Thromboembolism After Total Knee Arthroplasty |
|
|
| Completed | 2 | 156 | RoW | acetylsalicylic acid, Aspirin(Bayer), rivaroxaban, xarelto(bayer) | Hanyang University Seoul Hospital | Venous Thromboembolism | 01/16 | 02/16 | | |
| Completed | 2 | 64 | US, Canada, Europe, RoW | Rivaroxaban (Xarelto, BAY59-7939), Active comparator, Rivaroxaban (BAY59-7939) suspension | Bayer, Janssen Research & Development, LLC | Venous Thrombosis | 09/16 | 09/16 | | |
2016-003240-37: Study to evaluate the effect of rivaroxaban in patients with advanced liver disease with portal vein thrombosis Estudio para evaluar el efecto del rivaroxaban en pacientes con enfermedad hepática en fase avanzada con trombosis portal |
|
|
| Ongoing | 2 | 134 | Europe | Film-coated tablet, Xarelto® | Fundación para la Investigación Biomédica Hospital Ramón y Cajal, Carlos III Health Institute (National Health System) | Liver cirrhosis and portal vein thrombosis Cirrosis hepática y trombosis de la vena porta, Liver disease in advanced stage, with the possibility of developing portal vein thrombosis (occlusion of the vein that carries blood to the liver) Enfermedad hepática en fase avanzada, con posibilidad de desarrollar trombosis en la vena porta (oclusión de la vena que lleva la sangre al hÃgado), Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Completed | 2 | 46 | Canada, Japan, US, Europe, RoW | Rivaroxaban (Xarelto, BAY59-7939) | Bayer, Janssen Research & Development, LLC | Venous Thromboembolism | 04/17 | 04/17 | | |
2019-001723-12: Aspirin® plus rivaroxaban versus rivaroxaban alone for the prevention of venous stent thrombosis in patients with post-thrombotic syndrome (long-term condition associated with redness, swelling, leg pain, and ulcers as a results of deep vein thrombosis) |
|
|
| Not yet recruiting | 2 | 316 | Europe | Aspirin protect 100 mg, Film-coated tablet, Aspirin protect 100 mg | Universitätsspital Zürich, Klinik für Angiologie, Universitätsspital Zürich, Klinik für Angiologie, Bayer (Schweiz) AG, BARD Medica S.A. | Post-thrombotic syndrome, Post-thrombotic syndrome is a long-term complication of a deep vein thrombosis. It may include following symptoms: pain, swelling, itching , red/brown skin discoloration and ulcer at the affected leg., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR2000031649: A prospective, randomized, controlled study of rivaroxaban in the prevention of venous thrombosis in patients with deep vein catheterization chemotherapy for breast cancer |
|
|
| Completed | 2 | 200 | | rivaroxaban 10mg.po.qd ;Without preventive anticoagulant | Beijing Chaoyang District San Huan Cancer Hospital; Beijing Chaoyang District San Huan Cancer Hospital, Apply for funds from chaoyang district science and technology commission | Venous thrombosis of breast cancer | | | | |
PRIORITY, NCT03139487: A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism |
|
|
| Unknown status | 2 | 176 | RoW | Rivaroxaban, Xarelto, Dalteparin, Fragmin, apixaban, eliquis | Asan Medical Center | Cancer-associated Thrombosis, Esophageal Cancer, Stomach Cancer, Hepatocellular Carcinoma, Pancreatic Cancer, Duodenal Cancer, Esophagogastric Junction Cancer, Malignant Gastrointestinal Stromal Tumor, Ampulla of Vater Cancer, Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer) | 09/21 | 09/21 | | |
| Completed | 2 | 55 | Canada | Rivaroxaban, Xarelto, Standard of care, Heparin, Coumadin, Fragmin, Lovenox, Innohep | University of British Columbia | Cerebral Venous Thrombosis | 10/22 | 10/22 | | |
ARIVA, NCT04128956: Aspirin® Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With PTS |
|
|
| Terminated | 2 | 172 | Europe | Aspirin 100mg, Aspirin | University of Zurich, University Hospital Heidelberg, Medical University of Vienna, RWTH Aachen University, Klinikum Arnsberg, University Hospital Freiburg | Venous Thromboses, Stent Stenosis | 02/24 | 02/24 | | |
| Completed | 2 | 272 | Europe | Rivaroxaban 10 MG Oral Tablet [Xarelto] | Insel Gruppe AG, University Hospital Bern, Bayer, Janssen Pharmaceuticals | Bariatric Surgery | 12/23 | 12/23 | | |
NCT06220123: A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery |
|
|
| Not yet recruiting | 2 | 350 | NA | SHR-2004, Enoxaparin Sodium Injection; Rivaroxaban Tablets | Beijing Suncadia Pharmaceuticals Co., Ltd | Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery | 06/25 | 07/25 | | |
| Completed | 1/2 | 10 | Europe, RoW | Rivaroxaban (Xarelto, BAY59-7939) | Bayer, Janssen Research & Development, LLC | Thromboembolism | 12/17 | 12/17 | | |
NCT03747081: Efficacy Comparison of Warfarin Versus Rivaroxaban CVT |
|
|
| Unknown status | 1/2 | 50 | RoW | Rivaroxaban, Xarelto, Warfarin, Coumadin | Isfahan University of Medical Sciences | Cerebral Venous Thrombosis | 01/20 | 05/20 | | |
